DNX Corp. said Friday that it has filed for an initial publicoffering of 2.5 million shares of common stock with aproposed price of $13 to $15 per share. If the offering iscompleted, the Princeton, N.J., company will have about 9million shares outstanding.
In September, DNX raised $12.1 million in second-roundventure financing.
The company is developing transgenic animals to producehuman therapeutics such as human hemoglobin for use as ablood substitute and human serum albumin as a blood volumeexpander. DNX also provides biological testing services throughits Pharmakon Research International Inc. subsidiary.
Underwriters Hambrecht & Quist Inc. and Oppenheimer & Co.have a 375,000-share overallotment option.
(c) 1997 American Health Consultants. All rights reserved.